Skip to Main Content
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Darryl Martin, PhD

Assistant Professor

Contact Information

Darryl Martin, PhD

Research Summary

Dr. Martin’s interest encompasses both translational and biomedical research. His current research focuses on understanding the mechanisms involved in chemotherapeutic resistant bladder tumors as well as identifying the molecular signatures of heterogeneous prostate cancers. Dr. Martin uses patient derived tumors, primary cancer cells and cancer mouse models to develop novel therapies. He is currently funded by the Department of Defense to study tumor-homing nanoparticles for the imaging and treatment of prostate cancer.

Extensive Research Description

  • Project 1 attempts to understand the mechanism(s) involved in chemotherapeutic resistant bladder tumors
  • Project 2 aims to identify the molecular signatures of heterogeneous prostate cancers
  • Project 3 uses functionalized nanoparticles to locate and treat prostate cancer

Resistant bladder tumors; Heterogeneous prostate cancers; Tumor-homing nanoparticles

Coauthors

Research Interests

Urinary Bladder Neoplasms; Inflammation; Prostatic Neoplasms; Drug Delivery Systems; Cystitis, Interstitial; Biomedical Research; Nanomedicine; Translational Research, Biomedical; Tumor Microenvironment

Selected Publications

  • Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy.Choksi AU, Khan AI, Lokeshwar SD, Segal D, Weiss RM, Martin DT. Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy. American Journal Of Clinical And Experimental Urology 2022, 10: 142-153. PMID: 35874285, PMCID: PMC9301064.
  • Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted BiopsiesMartin DT, Ghabili K, Levi A, Humphrey PA, Sprenkle PC. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies Urology 2018, 125: 64-72. PMID: 30552940, DOI: 10.1016/j.urology.2018.12.001.
  • Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive ratHolmström F, Shimizu S, Shimizu T, Higashi Y, Martin DT, Honda M, Saito M. Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat The Prostate 2015, 75: 1774-1782. PMID: 26286428, DOI: 10.1002/pros.23063.
  • MP49-10 KNOCKDOWN OF GLYCOPROTEIN-130 INHIBITS BLADDER CANCER PROGRESSION AND MIGRATIONMartin D, Steinbach J, Wheeler M, Nawaf C, Saltzman W, Weiss R. MP49-10 KNOCKDOWN OF GLYCOPROTEIN-130 INHIBITS BLADDER CANCER PROGRESSION AND MIGRATION Investigative Urology 2015, 193: e606. DOI: 10.1016/j.juro.2015.02.514.
  • Blocking Glycoprotein‐130 Pathway Decreases Bladder Cancer GrowthMartin D, Steinbach J, Saltzman W, Weiss R. Blocking Glycoprotein‐130 Pathway Decreases Bladder Cancer Growth The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.889.11.
  • Blocking of the ATP sensitive potassium channel ameliorates the ischaemia‐reperfusion injury in the rat testisShimizu S, Oikawa R, Tsounapi P, Inoue K, Shimizu T, Tanaka K, Martin D, Honda M, Sejima T, Tomita S, Saito M. Blocking of the ATP sensitive potassium channel ameliorates the ischaemia‐reperfusion injury in the rat testis Andrology 2014, 2: 458-465. PMID: 24604784, DOI: 10.1111/j.2047-2927.2014.00199.x.
  • A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery.Hoimes C, Martin D, Kaimakliotis H, Cheng C, Kelly W, Tew G, Wheeler M, Weiss R, Saltzman W. A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery. Journal Of Clinical Oncology 2013, 31: e15543-e15543. DOI: 10.1200/jco.2013.31.15_suppl.e15543.
  • MP-04.16 Uptake of Surface Modified Poly(Lactide-Co-Glycolide) Nanoparticles in Bladder Cancer Cells and in Human Ureter and Mouse BladderWeiss R, Martin D, Steinbach J, Liu J, Kaimakliotis H, Wheeler M, Hittelman A, Saltzman W. MP-04.16 Uptake of Surface Modified Poly(Lactide-Co-Glycolide) Nanoparticles in Bladder Cancer Cells and in Human Ureter and Mouse Bladder Urology 2011, 78: s55. DOI: 10.1016/j.urology.2011.07.090.
  • 1055 SURFACE MODIFICATIONS OF POLY(LACTIDE-CO-GLYCOLIDE) NANOPARTICLES CAN INCREASE ITS UPTAKE BY BLADDER CANCER CELLSMartin D, Steinbach J, Kaimakliotis H, Liu J, Wheeler M, Hittelman A, Saltzman W, Weiss R. 1055 SURFACE MODIFICATIONS OF POLY(LACTIDE-CO-GLYCOLIDE) NANOPARTICLES CAN INCREASE ITS UPTAKE BY BLADDER CANCER CELLS Investigative Urology 2011, 185: e424. DOI: 10.1016/j.juro.2011.02.1092.
  • 1358 NANOPARTICLE DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR PXD101 FACILITATES BLADDER CANCER CELL UPTAKE AND CYTOTOXICITYKaimakliotis H, Martin D, Hoimes C, Cheng C, Liu J, Kelly K, Tew G, Saltzman W, Weiss R. 1358 NANOPARTICLE DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR PXD101 FACILITATES BLADDER CANCER CELL UPTAKE AND CYTOTOXICITY Investigative Urology 2011, 185: e542. DOI: 10.1016/j.juro.2011.02.1180.
Edit Profile